Mycobacterium avium strains resistant to clarithromycin and azithromycin

Mycobacterium avium strains susceptible to clarithromycin and azithromycin contain mutants resistant to these macrolides with a frequency of 1.1 x 10(-10) to 1.2 x 10(-6). Cross-resistance between clarithromycin and azithromycin was demonstrated with mutants selected in the laboratory as well as with resistant strains isolated from patients. The susceptibility-resistance patterns of the macrolide-resistant strains with drugs other than macrolides were the same as those of the original susceptible strains. The emergence of clarithromycin resistance in patients was a result of multiplication of the preexisting resistant mutants that survived the elimination of bacteria during the initial period of treatment and was an exclusive cause of the relapse of bacteremia.

[1]  L. Heifets,et al.  MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages , 1993, Antimicrobial Agents and Chemotherapy.

[2]  C. Truffot-Pernot,et al.  Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex , 1991, Antimicrobial Agents and Chemotherapy.

[3]  R. Bolan,et al.  Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS , 1991, The Lancet.

[4]  L. Heifets,et al.  Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. , 1992, The American review of respiratory disease.

[5]  Nalin Rastogi,et al.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex , 1991, Antimicrobial Agents and Chemotherapy.

[6]  C. Truffot-Pernot,et al.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages , 1991, Antimicrobial Agents and Chemotherapy.

[7]  Nalin Rastogi,et al.  Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents? , 1981, Antimicrobial Agents and Chemotherapy.

[8]  R. Wallace,,et al.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system , 1992, Antimicrobial Agents and Chemotherapy.

[9]  M. Nahata,et al.  The New Macrolide Antibiotics: Azithromycin, Clarithromycin, Dirithromycin, and Roxithromycin , 1992, The Annals of pharmacotherapy.

[10]  E. Gorzynski,et al.  Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin , 1989, Antimicrobial Agents and Chemotherapy.

[11]  S. Naik,et al.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex , 1989, Antimicrobial Agents and Chemotherapy.

[12]  P. Fernandes,et al.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium , 1989, Antimicrobial Agents and Chemotherapy.

[13]  D. Mitchison.  Development of Streptomycin Resistant Strains of Tubercle Bacilli in Pulmonary Tuberculosis , 1950, Thorax.

[14]  B. Dautzenberg,et al.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. , 1991, The American review of respiratory disease.

[15]  M. Cynamon,et al.  Activity of clarithromycin against Mycobacterium avium complex infection in beige mice , 1992, Antimicrobial Agents and Chemotherapy.

[16]  G. Youmans,et al.  Increase in resistance of tubercle bacilli to streptomycin; a preliminary report. , 1946, Proceedings of the staff meetings. Mayo Clinic.

[17]  C. Truffot-Pernot,et al.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages , 1990, Antimicrobial Agents and Chemotherapy.